Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer

Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer

Ovarian cancer is a leading cause of death among gynecological malignancies, and novel therapies are urgently needed. Here we report preliminary findings on the potential safety and efficacy of 6B11-OCIK, an adoptive cell therapy of autologous T cells induced by the humanized anti-idiotypic antibody...

Full description

Bibliographic Details
Main Authors: Hongyan Cheng, Ruiqiong Ma, Shang Wang, Yu Wang, Yingchun Li, Zhijian Tang, Sha Dou, Yuanfen Wang, Honglan Zhu, Xue Ye, Tianyu Zhang, Yonghua Zhang, Shufen Li, Yonghong Zhao, Yi Li, Heng Cui, Xiaohong Chang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
ovarian cancer
immunotherapy
adoptive cell therapy
safety and efficiency evaluation
circulating tumor cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.707468/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.707468/full

Similar Items